Neurocrine Biosciences Inc
(STU:NB3)
€
107.2
1.9 (1.8%)
Market Cap: 10.83 Bil
Enterprise Value: 10.11 Bil
PE Ratio: 35.07
PB Ratio: 4.67
GF Score: 88/100 Neurocrine Biosciences Inc at Stifel Virtual Healthcare Conference Transcript
Nov 16, 2020 / 04:20PM GMT
Release Date Price:
€78.46
(+1.37%)
Paul Andrew Matteis
Stifel, Nicolaus & Company, Incorporated, Research Division - Co-Head of the Biotech Team, MD & Senior Analyst
All right. Great. Thanks, everyone, for joining. Happy to be sitting here with CEO of Neurocrine, Kevin Gorman; and Kyle Gano, Chief Business Development Officer. Is that right, Kyle?
Kevin C. Gorman
Neurocrine Biosciences, Inc. - CEO & Director
Yes.
Kyle W. Gano
Neurocrine Biosciences, Inc. - Chief Business Development and Strategy Officer
That's right. Close enough.
Paul Andrew Matteis;Kevin C. Gorman
Stifel, Nicolaus & Company, Incorporated, Research Division - Co-Head of the Biotech Team, MD & Senior Analyst
Thank you. I appreciate it. So I think everyone knows Neurocrine well. I'm just going to ask Kevin to kind of quickly set the stage, review the recent update on INGREZZA and the pipeline, and then we'll get into Q&A. So Kevin, thanks again, and please take it away. Appreciate it.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot